Navigation Links
Intrexon Organizes Around New Synthetic Biology Markets
Date:5/9/2013

GERMANTOWN, Md., May 9, 2013 /PRNewswire/ -- Intrexon Corporation, a leader in synthetic biology that is helping companies design and develop products incorporating its Better DNA™, today announced it has aligned its industry markets to focus on four key sectors: Health, Food, Energy and Environment.

Intrexon currently has nine collaborations in Health and Food to create products embodying engineered bio-based solutions.  The goal of the new market alignment is to accelerate business development across all of Intrexon's key market sectors using the company's Exclusive Channel Collaboration (ECC) model.

Since Intrexon's founding in 1998 the company has developed its core technology, the UltraVector® platform, to accelerate development of genetically-enhanced products at industrial scale.  Using a dynamic library of more than two million diverse, modular genetic components, UltraVector enables the discovery, design, assembly and testing of a wide spectrum of multigenic biological systems.As part of its new market strategy, Intrexon named the following executives with deep industry experience to lead each market sector:

  • Health will be led by Dr. Samuel Broder , Executive Director of the Intrexon Institute for Biomolecular Research and former Director of the National Cancer Institute.
  • Food will be led by Dr. Thomas Kasser , with more than twenty-five years of senior management experience in agricultural biotechnology and animal health and nutrition, recognized as a Monsanto Fellow for his scientific and technical excellence.
  • Energy will be led by Robert Walsh , with over 30 years of global petroleum and chemical industry experience, including 26 years at Royal Dutch Shell.
  • Environment will be led by Nick Macris , with 15 years in the specialty chemical, water treatment, agricultural chemical and biopesticide industries with many large and small companies including 3M, Rohm and Haas, and FMC Corporation
  • Chairman and Chief Executive Officer Randal J. Kirk said the new market alignment will help Intrexon achieve its vision to be one of the leading life science companies in the world.

    "Our new sector organization, led by an outstanding team of industry veterans, will bring additional focus and rapidity to solving our partners' toughest synthetic biology problems," Kirk said.  "It's a very exciting step toward empowering the bioindustrial revolution with solutions that enhance the quality and diversity of life."

    About Intrexon CorporationIntrexon Corporation is a privately held biotechnology company focused on collaborating with companies in Health, Food, Energy and the Environment to create bio-based products that improve the quality of life and the health of the planet.  Through the company's proprietary UltraVector® platform, Intrexon provides its partners with industrial-scale design and development of multigenic biology.  UltraVector delivers unprecedented control over the quality, reliability, and performance of living cells.  We call it Better DNA™ and we invite you to discover more at www.dna.com.

    TrademarksIntrexon, UltraVector, mAbLogix and Better DNA are trademarks of Intrexon and/or its affiliates.  Other names may be trademarks of their respective owners.

    Safe Harbor StatementSome of the statements made in this press release are forward-looking statements.  These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

    For more information regarding Intrexon Corporation, contact:Corporate Contact:Investor Contact:Marie L. Rossi, Ph.D.The Ruth GroupManager, Technical Communications

    Intrexon Corporation

    Tel: +1 301-556-9944

    mrossi@intrexon.com

     Stephanie Carrington / Melanie Sollid-Penton

    Tel: +1 646-536-7017/7009

    scarrington@theruthgroup.com

    msollid@theruthgroup.com 

     


    '/>"/>
    SOURCE Intrexon Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
    2. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
    3. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
    4. Biodetection 2012 Conference Brings Together Leading Organizations from Around the World to Address Challenges & Technology Advances in Detection and Identification of Biological Threats in Washington, DC from June 28-29, 2012
    5. The Spring 2012 MediSend Biomedical Repair Training Program™ Sends Graduating Biomedical Technicians to Hospitals Around the World
    6. Physicists in Mainz and all around the world cheer the discovery of the Higgs particle
    7. BioInformatics LLC New Product Launch – RateMyProduct, a Quick Turnaround Product Assessment Tool for Life Science Suppliers
    8. Reliable electric power supply for the energy turn-around
    9. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
    10. Synthetic Biology: Emerging Global Markets
    11. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/24/2017)... , March 24, 2017  Infectex Ltd., a ... today announced positive results of a Phase 2b-3 clinical ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... at Sequella, Inc. ( USA ) and ... A total of 140 patients were enrolled in a ...
    (Date:3/24/2017)... March 24, 2017 Agenus Inc. (NASDAQ: AGEN), ... antibodies and cancer vaccines, today announced participation at the ...  Annual William Blair and Maidstone Life Sciences conference "Cancer ... in New York, NY . Agenus ... 29 at 9:40 am: Robert B. Stein , ...
    (Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
    (Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of the world,s ... systems, in terms of costs and resources. However, as the ... of innovative and efficient therapies that demonstrate higher chances of ... cancer treatments, a growing number of patients receiving immuno-oncology therapies ...
    Breaking Biology Technology:
    (Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
    (Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
    (Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
    Breaking Biology News(10 mins):